almagate has been researched along with Uveitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nuzzi, R; Tridico, F | 1 |
| Acquah, K; Day, S; Grossman, DS; Lee, PP; Mruthyunjaya, P; Sloan, FA | 1 |
| Heimann, H; Meyer, CH; Ziemssen, F | 1 |
1 review(s) available for almagate and Uveitis
| Article | Year |
|---|---|
[Intravitreal injection. Monitoring to avoid postoperative complications].
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract; Clinical Trials, Phase III as Topic; Endophthalmitis; Eye Hemorrhage; Female; Fetus; Hallucinations; Humans; Injections; Intraocular Pressure; Macular Degeneration; Mice; Paracentesis; Postoperative Complications; Pregnancy; Rabbits; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
2 other study(ies) available for almagate and Uveitis
| Article | Year |
|---|---|
Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Follow-Up Studies; Humans; Incidence; Intraocular Pressure; Intravitreal Injections; Male; Middle Aged; Odds Ratio; Ranibizumab; Retinal Detachment; Retinal Diseases; Retinal Hemorrhage; Retrospective Studies; Uveitis; Vascular Endothelial Growth Factor A | 2015 |
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Endophthalmitis; Eye Diseases; Female; Follow-Up Studies; Health Services Research; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Proportional Hazards Models; Ranibizumab; Retinal Detachment; Retinal Perforations; Retrospective Studies; United States; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Hemorrhage | 2011 |